Page 1 | Search Results | Cancer Discovery | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy

Cancer Discov (2024) 14 (9): 1631–1652.

https://doi.org/10.1158/2159-8290.CD-23-0798

Published: 04 September 2024

View article titled, Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy

Includes: Supplementary data

Journal Articles

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Cancer Discov (2018) 8 (2): 184–195.

https://doi.org/10.1158/2159-8290.CD-17-1119

Published: 04 February 2018

View article titled, First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Includes: Supplementary data

Journal Articles

A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?

Justin M. Balko, Jeffrey A. Sosman

Cancer Discov (2018) 8 (2): 143–145.

https://doi.org/10.1158/2159-8290.CD-17-1356

Published: 04 February 2018

View article titled, A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?

Journal Articles

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

Chunying Song, Marco Piva, Lu Sun, Aayoung Hong, Gatien Moriceau, Xiangju Kong, Hong Zhang, Shirley Lomeli, Jin Qian, Clarissa C. Yu, Robert Damoiseaux, Mark C. Kelley, Kimberley B. Dahlman, Philip O. Scumpia, Jeffrey A. Sosman, Douglas B. Johnson, Antoni Ribas, Willy Hugo, Roger S. Lo

Cancer Discov (2017) 7 (11): 1248–1265.

https://doi.org/10.1158/2159-8290.CD-17-0401

Published: 01 November 2017

View article titled, Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

Includes: Supplementary data

Journal Articles

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C. Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B. Johnson, Kimberly B. Dahlman, Mark C. Kelley, Richard F. Kefford, Bartosz Chmielowski, John A. Glaspy, Jeffrey A. Sosman, Nicolas van Baren, Georgina V. Long, Antoni Ribas, Roger S. Lo

Cancer Discov (2014) 4 (1): 80–93.

https://doi.org/10.1158/2159-8290.CD-13-0642

Published: 07 January 2014

View article titled, Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Includes: Supplementary data

Journal Articles

BRAF^L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

Cancer Discov (2012) 2 (9): 791–797.

https://doi.org/10.1158/2159-8290.CD-12-0097

Published: 10 September 2012

View article titled, BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

Includes: Supplementary data

Journal Articles

Preexisting MEK1 Exon 3 Mutations in ^V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Hubing Shi, Gatien Moriceau, Xiangju Kong, Richard C. Koya, Ramin Nazarian, Gulietta M. Pupo, Antonella Bacchiocchi, Kimberly B. Dahlman, Bartosz Chmielowski, Jeffrey A. Sosman, Ruth Halaban, Richard F. Kefford, Georgina V. Long, Antoni Ribas, Roger S. Lo

Cancer Discov (2012) 2 (5): 414–424.

https://doi.org/10.1158/2159-8290.CD-12-0022

Published: 09 May 2012

View article titled, Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Includes: Supplementary data

NARROW

Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

BRAF^L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

Preexisting MEK1 Exon 3 Mutations in ^V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Email alerts

AACR Journals

Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

BRAF^L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

Preexisting MEK1 Exon 3 Mutations in ^V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors